Requirement of Analgesics After Two Remifentanil Dosing Regimen in Cardiac Surgery. (REMISYD)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pasi Lahtinen, Kuopio University Hospital
ClinicalTrials.gov Identifier:
NCT00757198
First received: September 22, 2008
Last updated: September 11, 2013
Last verified: September 2013
  Purpose

Prospective double blind study comparing two remifentanil dosing protocols (0.1 and 0.3 mcg/kg/min) during cardiac surgery. Main outcome measures are postoperative opioid requirements (PCA oxycodone) and postoperative pain (VAS, verbal rating scale).


Condition Intervention Phase
Pain
Drug: remifentanil
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Requirement of Analgesics After Two Remifentanil Dosing Regimen in Cardiac Surgery.

Resource links provided by NLM:


Further study details as provided by Kuopio University Hospital:

Primary Outcome Measures:
  • Postoperative opioid (oxycodone) consumption [ Time Frame: Postoperatively 48 hours ] [ Designated as safety issue: No ]

Enrollment: 90
Study Start Date: September 2008
Study Completion Date: December 2011
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
remifentanil o.1 mcg/kg/min
Drug: remifentanil
remifentanil infusion
Active Comparator: 2
remifentanil 0.3 mcg/kg/min
Drug: remifentanil
remifentanil infusion

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Coronary artery bypass grafting patients

Exclusion Criteria:

  • Psychiatric disorders, sleep apnea, cardiac insufficiency
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00757198

Locations
Finland
Kuopio University hospital
Kuopio, Finland, 70210
Sponsors and Collaborators
Kuopio University Hospital
Investigators
Study Director: Pasi Lahtinen, MD Department of Anesthesiology and Intensive Care, Kuopio University hospital, Kuopio, Finland
  More Information

No publications provided

Responsible Party: Pasi Lahtinen, PhD,MD, Kuopio University Hospital
ClinicalTrials.gov Identifier: NCT00757198     History of Changes
Other Study ID Numbers: KUH5070206, EudraCT 2008-000597-21
Study First Received: September 22, 2008
Last Updated: September 11, 2013
Health Authority: Finland: Finnish Medicines Agency

Keywords provided by Kuopio University Hospital:
pain, postoperative, opioid, PCA, cardiac surgery

Additional relevant MeSH terms:
Remifentanil
Analgesics
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Therapeutic Uses
Hypnotics and Sedatives
Anesthetics, Intravenous
Anesthetics, General
Anesthetics

ClinicalTrials.gov processed this record on September 22, 2014